Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.

Chu-Yu LeeAmandeep KalraMaria V SpampinatoAli TabeshJens H JensenJoseph A HelpernMaria de Fatima FalangolaMark H Van HornPierre Giglio

Published in: The neuroradiology journal (2019)

This preliminary study demonstrates that diffusional kurtosis imaging metrics allow the detection of tissue changes 28 days after initiating bevacizumab treatment and that they may provide information about tumor progression.

Keyphrases

high resolution
magnetic resonance imaging
poor prognosis
computed tomography
combination therapy
social media
replacement therapy
label free
contrast enhanced